"Love is born from AI" Intel Artificial Intelligence Sharing Conference AI+Precision Medicine Special Session was successfully held in Beijing. Intel and partners from the artificial intelligence and life sciences industries Inspur , Novogene, Aier Ophthalmology and Jinhong Technology gathered together to analyze the profound changes that precision medicine has brought to the traditional medical industry and the role of artificial intelligence in precision medicine. The revolutionary innovations they bring will jointly promote the deployment and application of artificial intelligence in this field and accelerate the arrival of the era of precision medicine.
Intel Artificial Intelligence Sharing Conference AI+Precision Medicine Special Session was held in Beijing
As big data, cloud computing, etc. are gradually applied to hospital clinical operations, artificial intelligence is also bringing revolutionary changes to the medical industry. The ever-increasing computing power has greatly improved the data analysis capabilities and diagnostic level in the medical field. Combined with algorithm optimization and machine learning/deep learning technology, artificial intelligence will greatly improve the speed and accuracy of medical diagnosis, giving a powerful boost Innovation and progress in precision medicine.
As a data company, Intel has always insisted on product and technology innovation from cloud to end, and has worked extensively with partners to promote the development of cloud computing, big data, artificial intelligence and other technologies and solutions, providing driving force for business transformation in various industries. , in the field of precision medicine, Intel works with industry partners to accelerate popularization and innovation in this field. At the conference, Inspur announced the release of a new generation of gene all-in-one machine, based on Intel's integrated solution for the gene field BIGstack 1.0, and integrating Intel's latest Xeon scalable processor and FPGA co-processor. According to their measured data, taking whole-genome analysis as an example, the performance has been improved to more than 3 times compared with the previous generation. Liu Jun, general manager of Inspur's artificial intelligence and high-performance server product department, said: "The cooperation with Intel can better meet the needs of processing local genetic data analysis and provide better user experience and excellent performance. From solving genetic analysis Focus on efficiency issues to accelerate the development of precision medicine. "
Novogene has also adopted BIGstack genomics solutions and established a scalable genomics center based on RSD with Intel. Novogene CEO Li Ruiqiang said: " Performance, scalability, compatibility and manageability are critical to Novogene. Partnering with Intel will enable large-scale data processing capabilities to meet the needs of a global, scalable genomic data center model.”
Intel. Continuously unleash the power of artificial intelligence, accelerate the open transformation of the industry, support deployable solutions through a huge open ecosystem, and benefit all artificial intelligence. At the same time, Intel focuses on the integration of artificial intelligence technology with the medical field, adhering to the concept of popularizing artificial intelligence, and continuously launches easy-to-deploy and develop, high-performance deep learning platforms, using computing innovation to accelerate scientific research development and clinical applications in the field of precision medicine. .
Intel, together with AIER Ophthalmology, Jishi Internet, and Jinhong Technology, launched an artificial intelligence eye disease identification solution to further improve the accuracy and efficiency of diabetic retinopathy (DR) and age-related macular degeneration (AMD) screening. This helps many patients obtain early diagnosis and treatment. Tang Shibo, President of Aier Ophthalmology Group, said: "This artificial intelligence solution is based on Intel's hardware and deep learning platform. Based on the existing artificial intelligence recognition results of Aier Ophthalmology, it solves the problem of excessive reading volume during the medical treatment process by professional doctors. and other problems, greatly improving the efficiency of doctors’ clinical diagnosis.” Zheng Zhuming, chairman of Jinhong Technology, also said: "Through cooperation with Intel and AIER Ophthalmology, artificial intelligence can accelerate the ophthalmology diagnosis and treatment model and effectively solve social problems such as the scarcity of ophthalmologists and backward skills of primary hospitals."
Intel provides the most flexible and optimized solutions with its end-to-end full-stack strength. In the future, Intel will continue to integrate its advantages to provide the widest range of technology options for artificial intelligence and fully unleash its potential.Li Yadong, general manager of Intel Medical and Life Sciences Group Asia Pacific, said: "As a global leader in computing innovation, Intel is committed to continuous innovation and breakthroughs in artificial intelligence, and has in-depth cooperation with industry-leading partners in in-depth fields to accelerate artificial intelligence. The era of precision medicine is rapidly approaching, benefiting the public.”
